3
Participants
Start Date
April 30, 2008
Primary Completion Date
February 28, 2009
Study Completion Date
March 31, 2009
Melaxin (autologous dendritoma vaccine) and BCG
Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
Cancer Center of Carolinas/Clinical Research Unit 3rd Floor, Greenville
Collaborators (1)
Oncolix, Inc.
INDUSTRY
Prisma Health-Upstate
OTHER